Olema Pharmaceuticals (NASDAQ:OLMA) reported quarterly losses of $(0.36) per share which beat the analyst consensus estimate of $(0.51) by 29.41 percent. This is a 35.71 percent increase over losses of $(0.56) per share from the same period last year.